Currency In USD
| Previous Close | 8.91 |
| Open | 9.08 |
| Day High | 9.13 |
| Day Low | 8.89 |
| 52-Week High | 12.59 |
| 52-Week Low | 6.47 |
| Volume | 7,185 |
| Average Volume | 23,031 |
| Market Cap | 59.24M |
| PE | -5.56 |
| EPS | -1.62 |
| Moving Average 50 Days | 9.06 |
| Moving Average 200 Days | 8.58 |
| Change | 0.1 |
Xilio Therapeutics to Present at the Leerink Partners Global Healthcare Conference
GlobeNewswire Inc.
Mar 02, 2026 1:00 PM GMT
WALTHAM, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that compan
Xilio Therapeutics Announces Pricing of Underwritten Offering
GlobeNewswire Inc.
Feb 12, 2026 2:34 AM GMT
WALTHAM, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced the pricing
Xilio Therapeutics Highlights Upcoming Milestones and Recent Corporate Updates
GlobeNewswire Inc.
Jan 08, 2026 1:30 PM GMT
Received $35.8 million in gross proceeds from Series B warrant exercises, including full exercise by Coastlands Capital, Frazier Life Sciences and Gilead Sciences, Inc., and extended anticipated cash runway into second quarter of 2027 Achieved develo